Cyclin-dependent kinase inhibitor 1C

From Wikipedia, the free encyclopedia
Jump to: navigation, search
CDKN1C
Identifiers
Aliases CDKN1C, BWCR, BWS, KIP2, WBS, p57, p57Kip2, cyclin-dependent kinase inhibitor 1C, cyclin dependent kinase inhibitor 1C
External IDs HomoloGene: 133549 GeneCards: CDKN1C
Gene location (Human)
Chromosome 11 (human)
Chr. Chromosome 11 (human)[1]
Chromosome 11 (human)
Genomic location for CDKN1C
Genomic location for CDKN1C
Band No data available Start 2,883,213 bp[1]
End 2,885,881 bp[1]
RNA expression pattern
PBB GE CDKN1C 213182 x at fs.png

PBB GE CDKN1C 213348 at fs.png

PBB GE CDKN1C 216894 x at fs.png
More reference expression data
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_000076
NM_001122630
NM_001122631

n/a

RefSeq (protein)

NP_000067
NP_001116102
NP_001116103

n/a

Location (UCSC) Chr 11: 2.88 – 2.89 Mb n/a
PubMed search [2] n/a
Wikidata
View/Edit Human

Cyclin-dependent kinase inhibitor 1C (p57, Kip2), also known as CDKN1C, is protein which in humans is encoded by the CDKN1C imprinted gene.[3]

Function[edit]

Cyclin-dependent kinase inhibitor 1C is a tight-binding inhibitor of several G1 cyclin/Cdk complexes and a negative regulator of cell proliferation. Mutations of CDKN1C are implicated in sporadic cancers and Beckwith-Wiedemann syndrome suggesting that it is a tumor suppressor candidate.[3]

CDKN1C is a tumor suppressor human gene on chromosome 11 (11p15) and belongs to the cip/kip gene family. It encodes a cell cycle inhibitor that binds to G1 cyclin-CDK complexes.[4] Thus p57KIP2 causes arrest of the cell cycle in G1 phase.

Clinical significance[edit]

A mutation of this gene may lead to loss of control over the cell cycle leading to uncontrolled cellular proliferation. p57KIP2 has been associated with Beckwith-Wiedemann syndrome (BWS) which is characterized by increased risk of tumor formation in childhood.[5] Loss-of-function mutations in this gene have also been shown associated to the IMAGe syndrome (Intrauterine growth restriction, Metaphyseal dysplasia, Adrenal hypoplasia congenita, and Genital anomalies).[6] Complete hydatidiform moles consist only of paternal DNA, and thus the cells lack p57 expression as the gene is paternally imprinted (silenced). Immuohistochemical stains for p57 can aid with the diagnosis of hydatidiform moles [7]

Interactions[edit]

Cyclin-dependent kinase inhibitor 1C has been shown to interact with:

References[edit]

  1. ^ a b c ENSG00000129757 GRCh38: Ensembl release 89: ENSG00000273707, ENSG00000129757 - Ensembl, May 2017
  2. ^ "Human PubMed Reference:". 
  3. ^ a b "Entrez Gene: CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2)". 
  4. ^ Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ (Mar 1995). "p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene". Genes & Development. 9 (6): 650–62. PMID 7729684. doi:10.1101/gad.9.6.650. 
  5. ^ Hatada I, Nabetani A, Morisaki H, Xin Z, Ohishi S, Tonoki H, Niikawa N, Inoue M, Komoto Y, Okada A, Steichen E, Ohashi H, Fukushima Y, Nakayama M, Mukai T (Oct 1997). "New p57KIP2 mutations in Beckwith-Wiedemann syndrome". Human Genetics. 100 (5-6): 681–3. PMID 9341892. doi:10.1007/s004390050573. 
  6. ^ Riccio A, Cubellis MV (Jul 2012). "Gain of function in CDKN1C". Nature Genetics. 44 (7): 737–8. PMID 22735584. doi:10.1038/ng.2336. 
  7. ^ LeGallo, Robin D.; Stelow, Edward B.; Ramirez, Nilsa C.; Atkins, Kristen A. (2008-05-01). "Diagnosis of hydatidiform moles using p57 immunohistochemistry and HER2 fluorescent in situ hybridization". American Journal of Clinical Pathology. 129 (5): 749–755. ISSN 0002-9173. PMID 18426735. doi:10.1309/7XRL378C22W7APBT. 
  8. ^ Yokoo T, Toyoshima H, Miura M, Wang Y, Iida KT, Suzuki H, Sone H, Shimano H, Gotoda T, Nishimori S, Tanaka K, Yamada N (Dec 2003). "p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus". The Journal of Biological Chemistry. 278 (52): 52919–23. PMID 14530263. doi:10.1074/jbc.M309334200. 
  9. ^ Joaquin M, Watson RJ (Nov 2003). "The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain". The Journal of Biological Chemistry. 278 (45): 44255–64. PMID 12947099. doi:10.1074/jbc.M308953200. 
  10. ^ Reynaud EG, Leibovitch MP, Tintignac LA, Pelpel K, Guillier M, Leibovitch SA (Jun 2000). "Stabilization of MyoD by direct binding to p57(Kip2)". The Journal of Biological Chemistry. 275 (25): 18767–76. PMID 10764802. doi:10.1074/jbc.M907412199. 
  11. ^ Watanabe H, Pan ZQ, Schreiber-Agus N, DePinho RA, Hurwitz J, Xiong Y (Feb 1998). "Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen". Proceedings of the National Academy of Sciences of the United States of America. 95 (4): 1392–7. PMC 19016Freely accessible. PMID 9465025. doi:10.1073/pnas.95.4.1392. 

Further reading[edit]

External links[edit]